Skip to main content

$0.075 0.003 (4.17%)

High

$0.08

Low

$0.07

Trades

22

Turnover

$32,042

Volume

431,146
30 June 2023 at 3:55pm
Register to track IMC and receive email alerts.
Subject
IMC Ann: Half Yearly Report and Accounts

IMC Ann: Response to ASX Query

IMC Ann: Change in substantial holding

IMC Ann: Immuron Receives AUD $306,154 R&D Tax Concession Refund

IMC Ann: Immuron Receives European Patent on Drug to Treat Diarrhea

IMC Ann: Change in substantial holding

IMC Ann: Immuron awarded A$6.2 million US DoD funding for Travelan

IMC Ann: Change in substantial holding

IMC Ann: Application for quotation of securities - IMC

IMC Ann: Proposed issue of securities - IMC

IMC Ann: Investor Presentation

IMC Ann: Results of Meeting

IMC Ann: Change in substantial holding

IMC Ann: Notice of Annual General Meeting/Proxy Form

IMC Ann: US DoD Travelan Clinical Update

IMC Ann: Jobkeeper Payments Notification

IMC Ann: US DoD Naval Medical Research Center Clinical Update

IMC Ann: Notification regarding unquoted securities - IMC

IMC Ann: Application for quotation of securities - IMC

IMC Ann: Immuron filed XBRL data with the SEC

IMC Ann: Form 20-F filed with the SEC

IMC Ann: Amended Appendix 3H

IMC Ann: Notification of cessation of securities - IMC

IMC Ann: Change in substantial holding

IMC Ann: Change in substantial holding

IMC Ann: IMM124E Demonstrates Antiviral T-Cell Immunity

IMC Ann: Appendix 4G

IMC Ann: Corporate Governance Statement

IMC Ann: Annual Report to shareholders

IMC Ann: Director Resignation - Peter Anastasiou

IMC Ann: Reinstatement to Official Quotation

IMC Ann: Immuron planned Acquisition of R&D Vaccine Company

IMC Ann: Preliminary Final Report

IMC Ann: Market Update

IMC Ann: Market Update

IMC Ann: Change in substantial holding

IMC Ann: Voluntary Suspension

IMC Ann: Trading Halt

IMC Ann: Pause in Trading

IMC Ann: Change in substantial holding

IMC Ann: IMM124E May Offer New Modality for Inhibition of SARS-CoV-2

IMC Ann: Half Yearly Report and Accounts

IMC Ann: Change of Director's Interest Notice (RS)

IMC Ann: Appendix 2A and 708A

IMC Ann: Proposed issue of Securities - IMC

IMC Ann: Investor Presentation

IMC Ann: Immuron to Participate in BioConnect 2021 Virtual Conference

IMC Ann: Immuron SARS-CoV-2 Research Agreement with Monash University

IMC Ann: Change of Director's Interest Notice (DP)

IMC Ann: Immuron Receives AUD $358,280 R&D Tax Concession Refund

Register to track IMC and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX